Yes, LOTM, while I postulated on revenue flowing from TG 4010, I didn't address possible funds flow from TG 4001 or their other IP.
The funds flow from TG 4001 could be be a third of that from TG 4010 but the withdrawal of Roche was a setback for Transgene/Virax and the prospects for the drug are somewhat problematic.
Again, shareholders would be hoping for helpful disclosure when the independent reviewers report is filed in coming weeks.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.8¢ |
Change
0.001(3.70%) |
Mkt cap ! $48.11M | |||
| Open | High | Low | Value | Volume |
| 2.8¢ | 2.8¢ | 2.7¢ | $85.93K | 3.069M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300000 | 2.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.8¢ | 1231056 | 3 |
View Market Depth
| Last trade - 16.10pm 31/07/2025 (20 minute delay) ? |
| VHL (ASX) Chart |